Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:3711
Name bladder adenocarcinoma
Definition A bladder carcinoma that derives_from epithelial cells of glandular origin.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer urinary system cancer urinary bladder cancer bladder carcinoma bladder adenocarcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting USA 1
NCT03430895 Phase II Durvalumab + Tremelimumab Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract Completed USA 0
NCT03866382 Phase II Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Cabozantinib in Combination With Nivolumab and Ipilimumab in Rare Genitourinary Tumors Recruiting USA 1
NCT03912818 Phase II Cisplatin + Durvalumab + Gemcitabine Cisplatin + Doxorubicin + Durvalumab + Methotrexate + Vinblastine Carboplatin + Durvalumab + Gemcitabine Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer Active, not recruiting USA 0